Literature DB >> 15304259

Oxidative stress impairs glutamate uptake in fibroblasts from patients with Alzheimer's disease.

Barbara Begni1, Laura Brighina, Elena Sirtori, Lorenzo Fumagalli, Simona Andreoni, Simone Beretta, Thierry Oster, Catherine Malaplate-Armand, Valeria Isella, Ildebrando Appollonio, Carlo Ferrarese.   

Abstract

Oxidative stress has been demonstrated in Alzheimer's disease (AD) brain and may affect glutamate transport (GT), thereby leading to excitotoxic neuronal death. Since oxidative stress markers have been shown also in peripheral tissues, we investigated possible GT alterations in fibroblast cultures obtained from 18 patients with AD and 15 control patients and analyzed the effects of the lipoperoxidation product 4-hydroxynonenal (4-HNE) and antioxidants. Basal GT was decreased by 60% in fibroblasts from patients with AD versus control patients. Exposure to HNE did not affect GT in control patients, but it reduced GT by 50% in patients with AD, without any concomitant change in cell viability; conversely, HNE exposure induced a larger increase in ROS intracellular levels in AD than in control fibroblasts. Glutathione and N-acetylcysteine completely blocked 4-HNE effects and also increased basal uptake in AD cells. Moreover, inhibition of glutathione synthesis in control fibroblasts by pretreatment with buthionine sulfoximine resulted in GT reduction (40%) and an increase in ROS levels after exposure to 4-HNE. Nevertheless, since there are no differences between GSH basal level in controls and patients with AD, the alteration of other antioxidant systems cannot be excluded. Our study supports the hypothesis of a systemic impairment of GT in AD, possibly linked to oxidative stress and to reduced antioxidant defenses, which may be partially reversed by antioxidant treatment. Therefore, we suggest fibroblast cultures as a tool for exploring pathogenetic mechanisms and possible therapeutic strategies in patients with AD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15304259     DOI: 10.1016/j.freeradbiomed.2004.05.028

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  7 in total

1.  Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients.

Authors:  Xinglong Wang; Bo Su; Hisashi Fujioka; Xiongwei Zhu
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

Review 2.  Preventing Alzheimer's disease by means of natural selection.

Authors:  Lloyd A Demetrius; Jane A Driver
Journal:  J R Soc Interface       Date:  2015-01-06       Impact factor: 4.118

3.  4-Hydroxyhexenal (HHE) impairs glutamate transport in astrocyte cultures.

Authors:  Mark A Lovell; Melissa A Bradley; Shuling X Fister
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 4.  Thinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signaling.

Authors:  Richard Bridges; Victoria Lutgen; Doug Lobner; David A Baker
Journal:  Pharmacol Rev       Date:  2012-07       Impact factor: 25.468

5.  Riluzole partially rescues age-associated, but not LPS-induced, loss of glutamate transporters and spatial memory.

Authors:  Holly M Brothers; Isabelle Bardou; Sarah C Hopp; Roxanne M Kaercher; Angela W Corona; Ashley M Fenn; Jonathan P Godbout; Gary L Wenk
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-25       Impact factor: 4.147

6.  Guanidinoacetate inhibits glutamate uptake in rat striatum of rats at different ages.

Authors:  Alexandra I Zugno; Diogo L Oliveira; Emilene B S Scherer; Moacir Wajner; Susana Wofchuk; Angela T S Wyse
Journal:  Neurochem Res       Date:  2007-02-02       Impact factor: 4.414

7.  Human Dermal Fibroblast: A Promising Cellular Model to Study Biological Mechanisms of Major Depression and Antidepressant Drug Response.

Authors:  Pierre Mesdom; Romain Colle; Elise Lebigot; Séverine Trabado; Eric Deflesselle; Bruno Fève; Laurent Becquemont; Emmanuelle Corruble; Céline Verstuyft
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.